Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0482 Dose Escalation in R/R AML and CMML
NCT05038800Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of rolistobart in acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) (5 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Who Experienced a Dose-Limiting Toxicity, Number of Participants Who Experience at Least One Adverse Event up to 10 months and 1 more. Started Sep 2021; status: terminated.
02
Drugs
rolistobart
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05038800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038800.